Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA) Short Interest Up 5,048.9% in May

Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA) was the recipient of a significant growth in short interest during the month of May. As of May 29th, there was short interest totaling 315,885 shares, a growth of 5,048.9% from the May 14th total of 6,135 shares. Based on an average trading volume of 1,158,189 shares, the short-interest ratio is currently 0.3 days. Currently, 1.9% of the shares of the company are sold short.

Genenta Science Price Performance

NASDAQ GNTA traded down $0.20 on Tuesday, hitting $1.60. The stock had a trading volume of 457,874 shares, compared to its average volume of 1,391,427. Genenta Science has a one year low of $0.55 and a one year high of $10.00. The company has a debt-to-equity ratio of 0.35, a current ratio of 14.16 and a quick ratio of 14.16. The company’s 50-day moving average is $0.85 and its two-hundred day moving average is $1.10.

Genenta Science (NASDAQ:GNTA) last posted its earnings results on Tuesday, March 31st. The company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.36) by $0.28.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. SmartHarvest Portfolios LLC bought a new position in shares of Genenta Science in the fourth quarter valued at approximately $26,000. Citadel Advisors LLC bought a new position in shares of Genenta Science in the third quarter valued at approximately $41,000. Alyeska Investment Group L.P. bought a new position in shares of Genenta Science in the fourth quarter valued at approximately $328,000. Norges Bank bought a new position in shares of Genenta Science in the fourth quarter valued at approximately $337,000. Finally, Weiss Asset Management LP bought a new position in shares of Genenta Science in the fourth quarter valued at approximately $480,000. Institutional investors own 15.13% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Genenta Science in a report on Friday, March 27th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has an average rating of “Sell”.

About Genenta Science

Genenta Science (NASDAQ: GNTA) is a clinical-stage biotechnology company focused on the development of in vivo hematopoietic stem cell (HSC) gene therapies for the treatment of solid tumors. The company’s proprietary platform enables the transplantation of genetically engineered HSCs that home to tumor sites and continuously deliver immunomodulatory agents. By harnessing the patient’s own stem cells, Genenta aims to establish a sustained, localized anti-tumor immune response with the potential to overcome limitations of traditional cytokine or antibody therapies.

Genenta’s lead product candidate, Temferon, consists of autologous HSCs engineered to produce interferon-alpha under the control of a tumor microenvironment–activated promoter.